Drug intelligence / Profile preview

pegantiangiotide

Development stage: Unknown
Lead developer: Jiangsu Aotai Xin Biopharmaceutical Technology
Modality: Peptides
Administration: Subcutaneous

Overview

Pegantiangiotide (ATX-08) is a PEGylated synthetic peptide developed by Jiangsu Aotai Xin Biopharmaceutical Technology. It is designed as an anti-angiogenic therapy primarily for the treatment of rheumatoid arthritis (RA). The drug's mechanism involves the inhibition of pathological angiogenesis, a critical process in the formation of the synovial pannus and the progression of joint destruction in RA. By targeting angiogenic pathways, pegantiangiotide aims to reduce synovial inflammation and prevent structural damage to the joints. It has been investigated in clinical trials in China for its safety and efficacy in patients with active rheumatoid arthritis.

Other names: Pegylated anti-angiogenic peptide聚乙二醇化抗血管生成肽

Beyond the preview

Go deeper on pegantiangiotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pegantiangiotide.

Explore the full profile